As FLD is a very rare condition, just one patient was recruited to receive the therapy: a 34-year-old Japanese man homozygous for a missense mutation in the LACT gene. After implantation of LCAT ...

Commitment to the LCAT patient community for the creation of a patient association and assistance with early diagnosis In accordance with its Raison d'Etre as set out in its articles of ...

today provides an update on its progress and confirms its commitment to the rare disease known as LCAT Deficiency or ‘Norum's disease’. ABIONYX Pharma is a next-generation biopharma company ...